Abingdon Healt. Regulatory News (ABDX)

Abingdon Health plc

("Abingdon Health", the "Group" or the "Company")

UK Launch of LVOne Stroke Triage Test by UpFront Diagnostics

York, UK and Madison, WI, USA, 11 May 2026: Abingdon Health plc (AIM: ABDX) (OTCQB: ABDXF), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, notes the announcement on 5 May 2026 by its customer, UpFront Diagnostics, regarding the UK commercial launch of LVOne, the world's first rapid blood test for identifying a stroke at the point of care, following UKCA marking and the commencement of a deployment in partnership with London Ambulance Service ("LAS").

LVOne is designed to help paramedics identify patients likely to be experiencing a large vessel occlusion ("LVO") stroke in the pre-hospital setting. The test measures two blood biomarkers: D-dimer, associated with clot formation, and GFAP, associated with bleeding in the brain, to help differentiate stroke types and identify likely LVO patients, with results delivered in under 10 minutes from a finger-prick blood sample. Earlier identification of LVO enables paramedics to alert hospitals that a LVO patient is coming and allow them to prioritise time-critical treatment. An estimated 1.9 million brain cells are lost every minute following stroke onset.

Abingdon Health's role

Abingdon Health has acted as CDMO partner to Upfront Diagnostics for LVOne, delivering feasibility through scale-up, quality control, robustness testing, validation, and routine manufacture of the test's two assays. The programme navigated a number of technical challenges, including evolving project scope during technical transfer, inter-dependent dual-biomarker development, and complex reagent lead times. The successful UKCA marking and commercial launch of LVOne is a strong illustration of how the Company's CDMO capability, aids development through to deployment of a customer's lateral flow product.

The deployment

The initial deployment by UpFront Diagnostics will equip approximately 280 LAS vehicles serving North Central London, before expanding to North West and North East London, covering a population of approximately 6.5 million people, during a six-month pilot. The London programme is being led by Dr Robert Simister, consultant neurologist at the National Hospital for Neurology and Neurosurgery, University College London Hospitals (UCLH), in collaboration with LAS and several major stroke centres across the capital.

Gonzalo Ladreda, CEO and co-founder of UpFront Diagnostics, commented:

"Abingdon Health's expertise has been instrumental in bringing our stroke detection lateral flow test closer to reality."

Chris Yates, Chief Commercial Officer of Abingdon Health, commented:

"We are delighted to see LVOne reach UK patients following UKCA marking and to have supported UpFront Diagnostics as their CDMO partner and manufacturer on this important programme. LVOne is a powerful illustration of how lateral flow technology can be applied to time-critical clinical decision making in pre-hospital emergency care.

"Stroke is one of the leading causes of death and long-term disability in the UK, and the ability to identify likely LVO strokes within minutes, in the ambulance, has the potential to deliver meaningful improvements in patient outcomes. We congratulate the team at UpFront Diagnostics, London Ambulance Service and the clinical leadership at UCLH on this milestone, and we look forward to supporting UpFront Diagnostics as the programme progresses."

Any shareholders wishing to keep up to date with Abingdon Health news, please email abingdon@walbrookpr.com

Enquiries:

About Abingdon Health

Abingdon Health Group is a leading med-tech contract service provider offering its services to an international customer base.

The Group's CDMO (Contract Development and Manufacturing Organisation) expertise offers lateral flow product development, regulatory strategy support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from idea to commercial success.

Abingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Its consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring. The Company's subsidiary, Abingdon Analytical Ltd, offers analytical testing and performance evaluation to generate the required technical and data for regulatory approval for lateral flow and other in vitro diagnostic assays from its Doncaster, England facilities.

Founded in 2008, Abingdon Health is headquartered in York, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA.

Abingdon Health's brochures outlines the comprehensive support the Group can now provide to its international customers. For more information visit: www.abingdonhealth.com.

LEI - 213800XFI4WV3FBILO20